27392-68-3

Basic information

• Product Name: 1,5-NAPHTHYRIDIN-4-AMINE
• Synonyms: 1,5-NAPHTHYRIDIN-4-AMINE;1,5-NAPHTHYRIDIN-4-YLAMINE;1,5-Naphthyridine-4-amine;4-Amino-1,5-naphthyridine
• CAS NO: 27392-68-3
• Molecular Formula: C₈H₇N₃
• Molecular Weight: 145.16
• Mol File: 27392-68-3.mol

Chemical Properties

• Melting Point: 202-203 °C(Solv: water (7732-18-5))
• Boiling Point: 352.4°Cat760mmHg
• Flash Point: 194°C
• Appearance: /
• Density: 1.292g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.724
• Storage Temp.: 2-8°C
• PKA: 8.55±0.10(Predicted)
• CAS DataBase Reference: 1,5-NAPHTHYRIDIN-4-AMINE(CAS DataBase Reference)
• NIST Chemistry Reference: 1,5-NAPHTHYRIDIN-4-AMINE(27392-68-3)
• EPA Substance Registry System: 1,5-NAPHTHYRIDIN-4-AMINE(27392-68-3)

Safety Data

• Statements: 41
• Safety Statements: 26-39
• Hazardous Substances Data: 27392-68-3(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research:
1,5-Naphthyridin-4-amine is used as a building block for the synthesis of bioactive molecules and drugs, leveraging its chemical structure and properties to develop potential therapeutic agents for various diseases and conditions.
Used in Cancer Treatment:
1,5-Naphthyridin-4-amine is used as a potential therapeutic agent in the treatment of cancer, due to its biological activity and potential pharmacological effects that can contribute to the development of new cancer-fighting drugs.
Used in Inflammation Management:
1,5-Naphthyridin-4-amine is used as a compound with potential applications in managing inflammation, given its ability to be incorporated into the development of drugs that target inflammatory conditions.
Used in Drug Discovery and Development:
1,5-Naphthyridin-4-amine is used as a valuable compound in drug discovery and development, owing to its potential to contribute to the creation of new and effective medications for a range of medical conditions.

InChI:InChI=1/C8H7N3/c9-6-3-5-10-7-2-1-4-11-8(6)7/h1-5H,(H2,9,10)

Upstream product

• 7689-63-6 4-chloro-1,5-naphthyridine 
• 367953-14-8 trifluoro-methanesulfonic acid [1,5]naphthyridin-4-yl ester 
• 5423-54-1 4-hydroxy-1,5-naphthyridine 
• 27305-48-2 1,5-naphthyridine N-⁽¹⁾-oxide 
• 1394085-58-5 (4-methoxy-benzyl)-[1,5]naphthyridin-4-yl-amine 
• 254-79-5 1,5-naphthyridine 
• 90001-34-6 4-bromo-1,5-naphthyridine 

Downstream Products

• 792173-99-0 1-(2-methylbenzoxazol-6-yl)-3-(1,5-naphthyridin-4-yl)urea 
• 1394084-03-7 N-[1,5]Naphthyridin-4-yl-benzenesulfonamide 
• 1437789-70-2 (S)-4-(5,5-dimethyl-2-oxo-4-phenyloxazolidin-3-yl)-N-(1,5-naphthyridin-4-yl)benzamide 
• 1456505-89-7 (S)-4-(5,5-dimethyl-2-oxo-4-phenyloxazolidin-3-yl)-2-methyl-N-(1,5-naphthyridin-4-yl)benzamide 
• 1456507-45-1 (S)-2-(4-(5,5-dimethyl-2-oxo-4-phenyloxazolidin-3-yl)pyridin-2-yl)-N-(1,5-naphthyridin-4-yl)hydrazinecarboxamide 
• 1310550-13-0 C₁₅H₁₃N₅O 
• 1310549-83-7 C₁₅H₁₁N₅O₃ 

Relevant articles and documents

1,3-Biarylureas as selective non-peptide antagonists of the orexin-1 receptor

This communication reports SARs for the first orexin-1 receptor antagonist series of 1-aryl-3-quinolin-4-yl and 1-aryl-3-naphthyridin-4-yl ureas. One of these compounds, 31 (SB-334867), has excellent selectivity for the orexin-1 receptor, blood-brain barrier permeability and shows in vivo activity following ip dosing.

Novel Sulfonaminoquinoline Hepcidin Antagonists

The present invention relates to novel hepcidin antagonists, pharmaceutical compositions comprising them and the use thereof as medicaments for the use in the treatment of iron metabolism disorders, such as, in particular, iron deficiency diseases and anemias, in particular anemias in connection with chronic inflammatory diseases.

Hydrolytic instability of the important orexin 1 receptor antagonist SB-334867: Possible confounding effects on in vivo and in vitro studies

SB-334867 has been an important ligand for the study of the orexin 1 (OX1) receptor due to its high OX1/OX2 selectivity and bioavailability. This ligand however, contains a 2-methylbenzoxazole ring system which is known to undergo hydrolysis, particularly under acidic or basic conditions. The possibility that SB-334867 would be susceptible to significant hydrolysis was evaluated in various formulations and in the solid state. SB-334867 was found to be unstable under conditions commonly employed to prepare stock solutions for in vitro and in vivo studies. In addition, and most alarmingly, the hydrochloride salt of SB-334867 was found to quantitatively decompose to an OX1-inactive product even in the solid state. These findings combine to suggest that studies using SB-334867 (and any other 2-methylbenzoxazole-containing compound) should be performed with great care to avoid the confounding effects of the rapid hydrolytic decomposition of this susceptible structure.

ANTIANXIETY DRUGS AND A METHOD OF SCREENING THE SAME

An anxiolytic drug of the invention comprises an orexin receptor antagonist, a pharmacologically acceptable salt thereof, or a solvate thereof as an active ingredient. A method for screening a compound having an anxiolytic action of the invention comprises a step of using orexin-A.